[go: up one dir, main page]

SV2018005612A - Agentes, usos y metodos para el tratamiento de la sinucleinopatia - Google Patents

Agentes, usos y metodos para el tratamiento de la sinucleinopatia

Info

Publication number
SV2018005612A
SV2018005612A SV2018005612A SV2018005612A SV2018005612A SV 2018005612 A SV2018005612 A SV 2018005612A SV 2018005612 A SV2018005612 A SV 2018005612A SV 2018005612 A SV2018005612 A SV 2018005612A SV 2018005612 A SV2018005612 A SV 2018005612A
Authority
SV
El Salvador
Prior art keywords
disease
parkinson
sinucleinopatia
agents
treatment
Prior art date
Application number
SV2018005612A
Other languages
English (en)
Inventor
Pekka Kallunki
Karina Fogg
Louise Buur Vesterager
Ann Louise Bergström
Florence Sotty
De Brink Edward Van
Ibrahim John Malik
Liliana Christina Pereira Montezhino
Tom Vink
David Satjin
Paul Parren
Maker Rik Rade
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of SV2018005612A publication Critical patent/SV2018005612A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)

Abstract

LA INVENCIÓN SE REFIERE A NUEVOS ANTICUERPOS ANTI-ALFA-SINUCLEÍNA MONOCLONALES. LOS ANTICUERPOS PUEDEN USARSE PARA TRATAR UNA SINUCLEINOPATÍA TAL COMO LA ENFERMEDAD DE PARKINSON (INCLUYENDO FORMAS IDIOPÁTICAS Y HEREDITARIAS DE ENFERMEDAD DE PARKINSON), ENFERMEDAD DIFUSA CON CUERPOS DE LEWY (DLB), VARIANTE DE ENFERMEDAD DE ALZHEIMER CON CUERPOS DE LEWY (LBV), ENFERMEDAD COMBINADA DE ALZHEIMER Y PARKINSON, FALLO AUTONÓMICO PURO Y ATROFIA MULTISISTEMA
SV2018005612A 2015-07-13 2018-01-11 Agentes, usos y metodos para el tratamiento de la sinucleinopatia SV2018005612A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1512203.9A GB201512203D0 (en) 2015-07-13 2015-07-13 Agents,uses and methods

Publications (1)

Publication Number Publication Date
SV2018005612A true SV2018005612A (es) 2018-07-20

Family

ID=54013851

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2018005612A SV2018005612A (es) 2015-07-13 2018-01-11 Agentes, usos y metodos para el tratamiento de la sinucleinopatia

Country Status (40)

Country Link
US (12) US10800836B2 (es)
EP (2) EP4582144A3 (es)
JP (4) JP7012004B2 (es)
KR (2) KR102793383B1 (es)
CN (2) CN115925921A (es)
AR (1) AR105336A1 (es)
AU (1) AU2016292896B2 (es)
CL (1) CL2018000075A1 (es)
CO (1) CO2017012941A2 (es)
CR (2) CR20180021A (es)
DK (1) DK3322722T3 (es)
DO (1) DOP2018000013A (es)
EA (1) EA036499B1 (es)
EC (1) ECSP18002645A (es)
ES (1) ES3028882T3 (es)
FI (1) FI3322722T3 (es)
GB (1) GB201512203D0 (es)
GE (2) GEP20207151B (es)
HR (1) HRP20250624T1 (es)
HU (1) HUE071541T2 (es)
IL (1) IL256501B (es)
JO (1) JO3692B1 (es)
LT (1) LT3322722T (es)
MA (1) MA42439B1 (es)
MX (2) MX2018000504A (es)
MY (1) MY194944A (es)
NI (1) NI201800006A (es)
PE (1) PE20181049A1 (es)
PH (1) PH12018500016A1 (es)
PL (1) PL3322722T3 (es)
PT (1) PT3322722T (es)
RS (1) RS66840B1 (es)
RU (1) RU2765303C2 (es)
SI (1) SI3322722T1 (es)
SV (1) SV2018005612A (es)
TN (1) TN2018000005A1 (es)
TW (1) TWI729992B (es)
UA (1) UA125501C2 (es)
WO (1) WO2017009312A1 (es)
ZA (1) ZA201708607B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201512203D0 (en) * 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
JP7217229B2 (ja) * 2016-11-15 2023-02-02 ハー・ルンドベック・アクチエゼルスカベット シヌクレイノパチーの治療のための薬剤、使用および方法
US11325968B2 (en) 2016-12-16 2022-05-10 H. Lundbeck A/S Alpha-synuclein antibodies
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
MX2019008029A (es) 2017-01-06 2019-12-11 Abl Bio Inc Anticuerpo anti-alfa-sinucleina y su uso.
MX2019009117A (es) 2017-02-17 2019-09-13 Bristol Myers Squibb Co Anticuerpos anti alfa-sinucleina y usos de los mismos.
US10799484B2 (en) 2017-03-27 2020-10-13 Chase Therapeutics Corporation Compositions and methods for treating synucleinopathies
US11220538B2 (en) 2017-05-01 2022-01-11 The Trustees Of The University Of Pennsylvania Monoclonal antibodies against alpha-synuclein fibrils
WO2019040617A1 (en) 2017-08-23 2019-02-28 The Trustees Of The University Of Pennsylvania MONOCLONAL ANTIBODIES AGAINST PATHOLOGICAL ALPHA-SYNUCLEIN AND METHODS USING SAME
EP3725802A4 (en) * 2017-11-17 2021-08-11 ABL Bio Inc. Antibodies to alpha-synuclein and uses thereof
WO2019117684A1 (ko) 2017-12-14 2019-06-20 에이비엘바이오 주식회사 a-syn/IGF1R에 대한 이중 특이 항체 및 그 용도
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
EP3743918A1 (en) 2018-01-26 2020-12-02 Quantum-Si Incorporated Machine learning enabled pulse and base calling for sequencing devices
WO2019157527A2 (en) * 2018-02-12 2019-08-15 The Scripps Research Institute Methods related to parkinson's disease and synucleinopathies
EP3833435B1 (en) * 2018-08-09 2025-09-24 F. Hoffmann-La Roche AG Determination of parkinson's disease
TWI734279B (zh) * 2018-12-14 2021-07-21 美商美國禮來大藥廠 抗α-突觸核蛋白抗體及其用途
JP7689373B2 (ja) * 2019-04-18 2025-06-06 エイシー イミューン ソシエテ アノニム 治療及び診断のための新規分子
WO2020223310A2 (en) * 2019-04-29 2020-11-05 Thomas Jefferson University Methods for treating neurodegenerative disorders
US20250340623A1 (en) * 2019-12-04 2025-11-06 Ac Immune Sa Novel Molecules for Therapy and Diagnosis
KR102466943B1 (ko) * 2020-04-02 2022-11-14 한국과학기술연구원 갭을 갖는 바이오 센서를 이용한 파킨슨병 모니터링 방법 및 시스템
CN111537738A (zh) * 2020-05-18 2020-08-14 南通大学附属医院 用于超早期帕金森病检测的试剂盒
WO2023034914A2 (en) * 2021-09-01 2023-03-09 Vaxxinity, Inc. Methods for the prevention and treatment of synucleinopathies
EP4401770A2 (en) 2021-09-16 2024-07-24 H. Lundbeck A/S Compositions and methods for treating synucleinopathies
CN117430686B (zh) * 2022-07-22 2025-07-01 深圳市安群生物工程有限公司 α-突触核蛋白抗原表位肽及测定唾液中SNCA试剂盒和在帕金森病诊断中的应用
WO2024177999A2 (en) * 2023-02-21 2024-08-29 The Regents Of The University Of Michigan Human aggregated alpha-synuclein binding molecules
CN116077524A (zh) * 2023-02-27 2023-05-09 广西馨海药业科技有限公司 氯化铷在制备治疗帕金森综合征的药物中的用途
WO2025076635A1 (en) * 2023-10-12 2025-04-17 Universite Laval Anti-alpha-synuclein antibodies and uses thereof
WO2025186235A1 (en) 2024-03-05 2025-09-12 H. Lundbeck A/S Compositions and methods for treating multiple system atrophy (msa)

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
GB1512203A (en) 1974-05-08 1978-05-24 Aspin F Rolls for use in profiling film
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3788356T2 (de) 1986-12-15 1994-06-23 British Tech Group Usa Monomere phthalocyanin-reagenzien.
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ES2125854T3 (es) 1989-08-09 1999-03-16 Rhomed Inc Radiomarcado directo de anticuerpos y otras proteinas con tecnetio o renio.
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
CA2113113A1 (en) 1991-07-08 1993-01-21 Simon W. Kantor Thermotropic liquid crystal segmented block copolymer
WO1994019935A1 (en) 1993-03-09 1994-09-15 Genzyme Corporation Isolation of components of interest from milk
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
AU2753100A (en) 1999-02-03 2000-08-25 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
EP1210372B1 (en) 1999-07-29 2008-01-23 Medarex, Inc. Human monoclonal antibodies to her2/neu
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
CN1440420A (zh) 2000-07-07 2003-09-03 万能药制药公司 预防神经组织损伤和治疗α－共核蛋白疾病的方法
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
AU2002345843A1 (en) 2001-06-22 2003-01-08 Panacea Pharmaceuticals, Inc. Compositions and methods for preventing protein aggregation in neurodegenerative diseases
JP2005538706A (ja) 2001-07-12 2005-12-22 ジェファーソン フーテ， スーパーヒト化抗体
US8829198B2 (en) 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
US9034337B2 (en) * 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
DK2361928T3 (en) 2003-05-19 2017-07-03 Prothena Biosciences Ltd Truncated fragments of alpha synuclein in Lewy body disease
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
JP2006031250A (ja) 2004-07-14 2006-02-02 Fuji Xerox Co Ltd 通信装置およびその制御方法
MX2007001679A (es) 2004-08-09 2007-05-23 Elan Pharm Inc Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
US20060205024A1 (en) 2005-03-08 2006-09-14 Sun Health Research Institute Method to diagnose and evaluate progression of Alzheimer's disease
CA2657953A1 (en) 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto
KR20080090406A (ko) 2005-11-28 2008-10-08 젠맵 에이/에스 재조합 １가 항체 및 그의 제조 방법
EP2118300B1 (en) 2007-02-23 2015-05-27 Prothena Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
EP3067066B1 (en) 2007-02-23 2019-03-27 Prothena Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
CN104383556B (zh) * 2007-05-16 2018-06-05 布里格姆妇女医院 突触核蛋白病的治疗
US9693539B2 (en) 2007-08-10 2017-07-04 E. R. Squibb & Sons, L.L.C. HCO32 and HCO27 and related examples
TR201901497T4 (tr) 2008-04-29 2019-02-21 Bioarctic Ab Alfa-sinüklein ile ilişkili bozukluklar için terapötik ve teşhis yöntemlerinde kullanıma yönelik antikorlar ve aşılar.
CN102317316B (zh) * 2008-12-19 2014-08-13 帕尼玛制药股份公司 人抗α突触核蛋白自身抗体
ES2505243T3 (es) 2009-04-09 2014-10-09 Amicus Therapeutics, Inc. Agentes terapéuticos para prevenir y/o tratar trastornos degenerativos del sistema nervioso central
CN106397588B (zh) * 2010-02-26 2020-09-08 生命北极神经科学公司 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用
EP2366714A1 (en) 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
GB201008682D0 (en) 2010-05-25 2010-07-07 Vib Vzw Epitope tag for affinity based applications
MX345092B (es) 2010-10-11 2017-01-17 Univ Zuerich Anticuerpos anti-tau humanos,.
MX357193B (es) 2011-06-23 2018-06-29 Univ Zuerich Moleculas de union anti-alfa sinucleina.
JP2013059866A (ja) 2011-09-12 2013-04-04 Seiko Epson Corp 液体噴射装置、液体噴射装置の制御方法および液体噴射装置の制御プログラム
SMT202300048T1 (it) * 2011-10-28 2023-03-17 Prothena Biosciences Ltd Anticorpi umanizzati che riconoscono alfa-sinucleina
SG10201913370PA (en) 2012-07-03 2020-03-30 Univ Washington Antibodies to tau
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
CN104869993B (zh) 2012-10-25 2019-01-15 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
US9534044B2 (en) 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
JP2017504566A (ja) * 2013-11-21 2017-02-09 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗アルファ−シヌクレイン抗体及び使用方法
US9732148B2 (en) 2014-10-16 2017-08-15 Genentech, Inc. Anti-α-synuclein antibodies and methods of use
KR20180021693A (ko) 2015-05-07 2018-03-05 엑소반트 사이언시즈 게엠베하 신경퇴행성 질환을 치료하는 조성물 및 방법
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
HUE057214T2 (hu) 2016-06-02 2022-04-28 Medimmune Ltd Alfa-szinuklein elleni ellenanyagok és alkalmazásuk
JP7217229B2 (ja) 2016-11-15 2023-02-02 ハー・ルンドベック・アクチエゼルスカベット シヌクレイノパチーの治療のための薬剤、使用および方法
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation

Also Published As

Publication number Publication date
JP2021191763A (ja) 2021-12-16
PL3322722T3 (pl) 2025-06-30
RS66840B1 (sr) 2025-06-30
TWI729992B (zh) 2021-06-11
US20180179270A1 (en) 2018-06-28
GEP20207151B (en) 2020-09-25
CN107709361A (zh) 2018-02-16
ECSP18002645A (es) 2018-03-31
MA42439A (fr) 2018-05-23
WO2017009312A1 (en) 2017-01-19
RU2765303C2 (ru) 2022-01-28
MX2023009483A (es) 2023-08-22
HK1254358A1 (en) 2019-07-19
ZA201708607B (en) 2019-05-29
CR20180021A (es) 2018-03-13
DK3322722T3 (da) 2025-05-26
JO3692B1 (ar) 2020-08-27
CA2989735A1 (en) 2017-01-19
RU2017145653A3 (es) 2019-11-21
US20190367594A1 (en) 2019-12-05
JP7608404B2 (ja) 2025-01-06
SI3322722T1 (sl) 2025-06-30
TN2018000005A1 (en) 2019-07-08
US11542323B2 (en) 2023-01-03
HUE071541T2 (hu) 2025-09-28
ES3028882T3 (en) 2025-06-20
US20210061892A1 (en) 2021-03-04
AU2016292896A1 (en) 2018-01-18
PE20181049A1 (es) 2018-07-03
US10640554B2 (en) 2020-05-05
UA125501C2 (uk) 2022-04-13
BR112017027506A2 (pt) 2018-09-11
US10358483B2 (en) 2019-07-23
US20190367595A1 (en) 2019-12-05
MX2018000504A (es) 2018-04-30
US20180127492A1 (en) 2018-05-10
JP2018529634A (ja) 2018-10-11
NI201800006A (es) 2018-10-18
US10358484B2 (en) 2019-07-23
US20180179271A1 (en) 2018-06-28
CL2018000075A1 (es) 2018-05-11
JP2022174131A (ja) 2022-11-22
US20170015739A1 (en) 2017-01-19
PT3322722T (pt) 2025-05-21
PH12018500016A1 (en) 2018-07-09
CR20230300A (es) 2023-08-25
US20210054057A1 (en) 2021-02-25
JP7138322B2 (ja) 2022-09-16
US10364285B2 (en) 2019-07-30
GEAP202014670A (en) 2020-05-11
EA036499B1 (ru) 2020-11-17
FI3322722T3 (fi) 2025-06-05
EP4582144A2 (en) 2025-07-09
US20210147522A1 (en) 2021-05-20
AR105336A1 (es) 2017-09-27
US10358482B2 (en) 2019-07-23
CO2017012941A2 (es) 2018-03-09
GB201512203D0 (en) 2015-08-19
JP7012004B2 (ja) 2022-02-10
AU2016292896B2 (en) 2022-02-24
US20190382473A1 (en) 2019-12-19
US10800836B2 (en) 2020-10-13
CN115925921A (zh) 2023-04-07
US20180127491A1 (en) 2018-05-10
DOP2018000013A (es) 2018-04-15
TW201716440A (zh) 2017-05-16
LT3322722T (lt) 2025-06-10
EP3322722B1 (en) 2025-03-05
MY194944A (en) 2022-12-27
IL256501B (en) 2021-10-31
IL256501A (en) 2018-02-28
EP4582144A3 (en) 2025-07-16
US10647763B2 (en) 2020-05-12
MA42439B1 (fr) 2025-05-30
NZ738315A (en) 2024-12-20
US20230312693A1 (en) 2023-10-05
RU2017145653A (ru) 2019-08-13
KR20250051158A (ko) 2025-04-16
US11524995B2 (en) 2022-12-13
US10647764B2 (en) 2020-05-12
KR20180029205A (ko) 2018-03-20
EP3322722A1 (en) 2018-05-23
JP2025041734A (ja) 2025-03-26
KR102793383B1 (ko) 2025-04-08
US11421024B2 (en) 2022-08-23
EA201792616A1 (ru) 2018-06-29
HRP20250624T1 (hr) 2025-07-18

Similar Documents

Publication Publication Date Title
SV2018005612A (es) Agentes, usos y metodos para el tratamiento de la sinucleinopatia
CO2019004755A2 (es) Agentes, usos y métodos para el tratamiento de la sinucleinopatía
CL2020000299A1 (es) Compuestos, composiciones y métodos.
DOP2019000040A (es) Compuestos de pirrolizina sustituidas y usos de los mismos
AR113881A1 (es) Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia
GT201700072A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
MX2018013472A (es) Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares.
ECSP19015192A (es) Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
GT201700188A (es) Anticuerpos contra tau y sus usos
MX388562B (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX2016016301A (es) Procesos de siembra en serie y usos de los mismos.
MX395231B (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos.
EA201991997A1 (ru) Комбинированная терапия
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
BR112016017776A2 (pt) Formas sólidas de 2-(terc-butilamino)-4-((1r,3r,4r)-3-hidróxi-4-metil-ciclo-hexilamino)-pirimidina-5-carboxamida, composições das mesmas e métodos para seu uso
SV2016005293A (es) Compuestos de azol amido-sustituidos como inhibidores de tnks1 y/o tnks2
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2018003109A1 (es) Formas polimorficas de 3-[2-butil-1-(2-dietilamino-etil-1h-benzoimidazol-5-yl]-n-hidroxi-acrilamida y sus usos.
MX2018013943A (es) Metodo de tratamiento de hiperglucemia.
MX384637B (es) Compuestos oxadiazoespíricos para el tratamiento del abuso y la adicción a las drogas.
MX2019002673A (es) Composiciones y metodos para tratar demencia.
MX2017011904A (es) Composiciones para el tratamiento de fibrosis y afecciones relacionadas con fibrosis.